TABLE III.
Main results
| Variable | Adjuvant | Metastatic | Overall | |
|---|---|---|---|---|
|
| ||||
| Non-resected | Resected | |||
| Patients (n) | 29 | 20 | 8 | 57 |
| Cumulative dose (mg/m2) | ||||
| Mean | 647.3 | 671.2a | 944.0a | 697.3 |
| Range | 85–1020 | 200–1255 | 595–1110 | 85–1255 |
| Cycles (n) | ||||
| Mean | 7.9 | 7.5 | 10.8 | 8.2 |
| Range | 1–12 | 2–15 | 7–12 | 1–15 |
| Change in therapy because of neuropathy [n (%)] | ||||
| Dose reduction | 9 (31.0) | 5 (25.0) | 1 (12.5) | 15 (26.3) |
| Treatment cessation | 8 (27.6) | 6 (30.0) | 0 | 14 (24.6) |
| Worst neuropathy during treatmentb [n (%)] | ||||
| Grade 1 | 3 (10.3) | 4 (20.0) | 3 (37.5) | 10 (18.2) |
| Grade 2 | 18 (62.1) | 11(55.0) | 4 (50.0) | 33 (57.9) |
| Grade 3 | 6 (20.7) | 5 (25.0) | 0 | 11 (19.2) |
a
At 12 months.
b
Using the U.S. National Cancer Institute’s Common Toxicity Criteria, version 4. Three patients had no neuropathy, and no grade 4 peripheral sensory neuropathies were reported.